Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. (2023)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/2767-9764.crc-23-0111
PubMed Identifier: 37520743
Publication URI: http://europepmc.org/abstract/MED/37520743
Type: Journal Article/Review
Volume: 3
Parent Publication: Cancer research communications
Issue: 7
ISSN: 2767-9764